Previous close | 0.0941 |
Open | 0.0890 |
Bid | 0.0842 x 1200 |
Ask | 0.0853 x 1800 |
Day's range | 0.0881 - 0.0929 |
52-week range | 0.0810 - 5.9800 |
Volume | |
Avg. volume | 13,409,670 |
Market cap | 3.549M |
Beta (5Y monthly) | 0.59 |
PE ratio (TTM) | N/A |
EPS (TTM) | -5.2200 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal second quarter ended December 31, 2023, and provided a corporate update.
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the initiation of a REM-001 15-patient clinical trial (NCT05374915) in cutaneous metastatic breast cancer (CMBC) patients.
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value.